Quadrant Capital Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Quadrant Capital Group’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3	Closed	-$71	–	2384
2026 Q1	$71	Hold	3	–	–	﹤0.01%	2698
2025 Q4	$64	Hold	3	–	–	﹤0.01%	2698
2025 Q3	$47	Buy	+3	New	+$39	﹤0.01%	2667
2025 Q2	–	Sell	-194	Closed	-$2.38K	–	2434
2025 Q1	$2.38K	Sell	194 -824	-81%	-$11.6K	﹤0.01%	2487
2024 Q4	$13.5K	Sell	1,018 -1,661	-62%	-$28.4K	﹤0.01%	2034
2024 Q3	$51.6K	Buy	2,679 +187	+8%	+$3.86K	﹤0.01%	1435
2024 Q2	$51.2K	Sell	2,492 -75	-3%	-$1.57K	﹤0.01%	1394
2024 Q1	$61.1K	Buy	2,567 +126	+5%	+$2.81K	﹤0.01%	1277
2023 Q4	$52.8K	Buy	2,441 +1,496	+158%	+$23K	﹤0.01%	1359
2023 Q3	$13.7K	Buy	945 +933	+7,775%	+$17.6K	﹤0.01%	1867
2023 Q2	$252	Sell	12 -116	-91%	-$2.42K	﹤0.01%	2641
2023 Q1	$2.7K	Hold	128	–	–	﹤0.01%	2371
2022 Q4	$3.26K	Hold	128	–	–	﹤0.01%	2306
2022 Q3	$3K	Hold	128	–	–	﹤0.01%	2298
2022 Q2	$2K	Buy	+128	New	+$2.13K	﹤0.01%	2280

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Quadrant Capital Group's SNDX Position: Q2 2026 in Review

Quadrant Capital Group sold out of Syndax Pharmaceuticals (SNDX) in Q2 2026, closing a stake of 3 shares — an estimated $71 sold.

Quadrant Capital Group first reported a position in SNDX in Q2 2022 and held it in 15 quarters. The position peaked at $61.1K in Q1 2024. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Quadrant Capital Group reported no remaining Syndax Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Quadrant Capital Group sold 3 Syndax Pharmaceuticals shares in Q2 2026, an estimated $71.
Quadrant Capital Group first reported a position in Syndax Pharmaceuticals in Q2 2022 and held it in 15 quarters.
Quadrant Capital Group's Syndax Pharmaceuticals position peaked at $61.1K in Q1 2024.
242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.